

Dorota ZarÄbska-Michaluk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7630442/publications.pdf>

Version: 2024-02-01

84
papers

935
citations

567281

15
h-index

610901

24
g-index

92
all docs

92
docs citations

92
times ranked

1200
citing authors

#	ARTICLE	IF	CITATIONS
1	Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?. <i>Viruses</i> , 2022, 14, 96.	3.3	9
2	HCV Genotype Has No Influence on the Incidence of Diabetes – EpiTer Multicentre Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 379.	2.4	2
3	Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection. <i>Journal of Clinical Medicine</i> , 2022, 11, 389.	2.4	2
4	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. <i>Human Genetics</i> , 2022, 141, 147-173.	3.8	22
5	HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons. <i>Viruses</i> , 2022, 14, 482.	3.3	9
6	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of February 23, 2022. <i>Polish Archives of Internal Medicine</i> , 2022, 132, .	0.4	14
7	Does Hospitalization Change the Perception of COVID-19 Vaccines among Unvaccinated Patients?. <i>Vaccines</i> , 2022, 10, 476.	4.4	16
8	Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland. <i>Vaccines</i> , 2022, 10, 557.	4.4	15
9	Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection. <i>Dermatologic Therapy</i> , 2022, 35, e15274.	1.7	3
10	Demographic and Clinical Overview of Hospitalized COVID-19 Patients during the First 17 Months of the Pandemic in Poland. <i>Journal of Clinical Medicine</i> , 2022, 11, 117.	2.4	18
11	The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland. <i>Environmental Pollution</i> , 2022, 306, 119469.	7.5	20
12	Retinal Microvascular Changes in COVID-19 Bilateral Pneumonia Based on Optical Coherence Tomography Angiography. <i>Journal of Clinical Medicine</i> , 2022, 11, 3621.	2.4	9
13	Ways to Eliminate Viral Hepatitis as a Global Health Threat. <i>Viruses</i> , 2022, 14, 1554.	3.3	3
14	Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 93-100.	4.4	34
15	Genotype 3-hepatitis C virus – last line of defense. <i>World Journal of Gastroenterology</i> , 2021, 27, 1006-1021.	3.3	9
16	Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: EpiTer2 Study. <i>Liver International</i> , 2021, 41, 1789-1801.	3.9	10
17	Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. <i>Journal of Clinical Medicine</i> , 2021, 10, 1583.	2.4	21
18	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 487-496.	0.4	48

#	ARTICLE	IF	CITATIONS
19	Impact of Kidney Failure on the Severity of COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 2042.	2.4	13
20	Rapid serological tests for SARS-CoV-2 IgG/IgM â€œ not worth attention?. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2021, 34, 203-209.	1.3	1
21	Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. <i>World Journal of Gastroenterology</i> , 2021, 27, 2177-2192.	3.3	5
22	Is elimination of HCV in 2030 realistic in Central Europe. <i>Liver International</i> , 2021, 41, 56-60.	3.9	9
23	Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3359-3366.	3.5	17
24	Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. <i>Journal of Clinical Medicine</i> , 2021, 10, 3280.	2.4	13
25	Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. <i>Vaccines</i> , 2021, 9, 781.	4.4	28
26	Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy. <i>Cancers</i> , 2021, 13, 3694.	3.7	16
27	Genotype-specific versus pangenotypic regimens in patients infected with HCV genotype 1b in real-world settings. <i>Polish Archives of Internal Medicine</i> , 2021, 131, .	0.4	2
28	Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study. <i>Annals of Gastroenterology</i> , 2021, 34, 438-446.	0.6	2
29	Convalescent Plasma Transfusion for the Treatment of COVID-19â€”Experience from Poland: A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 28.	2.4	23
30	Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination. <i>Vaccines</i> , 2021, 9, 1325.	4.4	8
31	Diagnosis and therapy of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of November 12, 2021. Annex no. 1 to the Recommendations of April 26, 2021. <i>Polish Archives of Internal Medicine</i> , 2021, 131, .	0.4	6
32	Gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)- enhanced magnetic resonance imaging with various enhancement ratios: a correlation with clinical assessment of liver function using the Child-Pugh scoring system. <i>Studia Medyczne</i> , 2021, 37, 279-287.	0.1	0
33	Real life results of direct acting antiviral therapy for HCV infection in HIVâ€œHCV-coinfected patients: Epi-Ter2 study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 762-769.	1.2	12
34	Realâ€œworld experience with Grazoprevir/Elbasvir in the treatment of previously â€œdifficult to treatâ€œ patients infected with hepatitis C virus genotype 1 and 4. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1238-1246.	2.8	9
35	Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. <i>Advances in Medical Sciences</i> , 2020, 65, 12-17.	2.1	5
36	Is an 8â€œweek regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the realâ€œworld experience?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 36, 1944-1952.	2.8	9

#	ARTICLE	IF	CITATIONS
37	Searching for the optimal population for hepatitis C virus screening in Poland. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 74-76.	1.3	3
38	Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfecting patients treated with DAA. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1045-1054.	4.4	12
39	How close are we to hepatitis C virus elimination in Central Europe?. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 1-8.	1.3	11
40	Management of hepatitis B and hepatitis C coinfection: an expert review. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1033-1044.	4.4	5
41	Changes of patient profile, treatment effectiveness and safety during 4 years access to interferon-free therapy for hepatitis C virus infection. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 163-172.	0.4	14
42	Recommendations of management in SARS-CoV-2 infection of the Polish Association of Epidemiologists and Infectiologists. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 352-357.	0.4	51
43	Annex #1 as of 8 June 2020 to: Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 557-558.	0.4	20
44	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 915-918.	0.4	30
45	Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study. <i>Polish Archives of Internal Medicine</i> , 2020, 131, 103-110.	0.4	12
46	Knowledge is coming so fast that a meta-analysis of COVID-19 treatment is always too late. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 721-723.	0.4	0
47	Pulmonary embolism complicating the course of COVID-19 – an underestimated condition?. <i>Studia Medyczne</i> , 2020, 36, 206-210.	0.1	2
48	THU-197-Comparative effectiveness of 8 versus 12 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2019, 70, e250.	3.7	0
49	THU-217-Low risk of HBV reactivation in a large European cohort of HBV/ HCV coinfecting patients treated with DAA. <i>Journal of Hepatology</i> , 2019, 70, e259.	3.7	1
50	Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 215-223.	1.3	1
51	Perspectives of hepatitis C virus (HCV) elimination in Poland. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 210-214.	1.3	6
52	THU-185-Effectiveness and safety of DAA-based treatment of hepatitis C patients with severe and end stage chronic kidney diseases-EpiTer-2 database analysis. <i>Journal of Hepatology</i> , 2019, 70, e243-e244.	3.7	0
53	THU-196-Efficacy of 8 versus 12-weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-weeks regimen in real world setting. <i>Journal of Hepatology</i> , 2019, 70, e249-e250.	3.7	0
54	Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-9.	1.9	12

#	ARTICLE	IF	CITATIONS
55	Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real-world setting. Archives of Medical Science, 2019, , .	0.9	2
56	Viral hepatitis C treatment shortening â€“ what is the limit?. Clinical and Experimental Hepatology, 2019, 5, 265-270.	1.3	4
57	Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?. Journal of Interferon and Cytokine Research, 2018, 38, 93-100.	1.2	9
58	Treatment of <sc>HCV</sc> infection in Poland at the beginning of the interferonâ€free eraâ€”the EpiTerâ€2 study. Journal of Viral Hepatitis, 2018, 25, 661-669.	2.0	22
59	The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. BMC Infectious Diseases, 2018, 18, 580.	2.9	2
60	The efficacy of paritaprevir/ritonavir/ombitasvir + dasabuvir and ledipasvir/sofosbuvir is similar in patients who failed interferon-based treatment with first generation protease inhibitors. Journal of Hepatology, 2018, 68, S277.	3.7	0
61	Risk of de novo hepatocellular carcinoma after DAA treatment within two years following treatment with Ombitasvir/Paritaprevir/ritonavir Â± Dasabuvir Â± Ribavirin in the AMBER â€“ real world experience study. Journal of Hepatology, 2018, 68, S536.	3.7	2
62	Real world experience with twelve weeks of therapy without ribavirin in genotype 1 HCV infected compensated cirrhotics. Journal of Hepatology, 2018, 68, S296-S297.	3.7	0
63	Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2Âyears after treatment with ombitasvir/paritaprevir/ritonavirÂ±dasabuvirÂ±ribavirin in the AMBER, realâ€world experience study. Journal of Viral Hepatitis, 2018, 25, 1298-1305.	2.0	19
64	Retreatment of symptomatic hepatitis C virus genotype 3 associated mixed cryoglobulinemia with sofosbuvir and ribavirin: a case report. Clinical and Experimental Hepatology, 2018, 4, 100-103.	1.3	2
65	Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. Hepatitis Monthly, 2018, 18, .	0.2	2
66	Effectiveness and safety of ledipasvir/sofosbuvir Â± ribavirin in the treatment of HCV infection: The real-world HARVEST study. Advances in Medical Sciences, 2017, 62, 387-392.	2.1	23
67	Megamitochondria formation in hepatocytes of patient with chronic hepatitis C â€“ a case report. Clinical and Experimental Hepatology, 2017, 3, 169-175.	1.3	12
68	Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection. Clinical and Experimental Hepatology, 2016, 3, 117-124.	1.3	2
69	Efficacy of HCV treatment in Poland at the turn of the interferon era â€“ the EpiTer study. Clinical and Experimental Hepatology, 2016, 4, 138-143.	1.3	16
70	Prevalence of HCV genotypes in Poland â€“ the EpiTer study. Clinical and Experimental Hepatology, 2016, 4, 144-148.	1.3	18
71	Realâ€world effectiveness and safety of ombitasvir/paritaprevir/ritonavirÂ±Â±dasabuvirÂ±Â±ribavirin in hepatitis C: AMBER study. Alimentary Pharmacology and Therapeutics, 2016, 44, 946-956.	3.7	82
72	Daclatasvir<i>vs</i>telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World Journal of Gastroenterology, 2016, 22, 3418-3431.	3.3	17

#	ARTICLE	IF	CITATIONS
73	Treatment of Acute Hepatitis C. <i>Journal of Microbiology and Infectious Diseases</i> , 2016, 6, .	0.1	0
74	Severe intrahepatic cholestasis and liver failure after stanozolol usage “ and review of the literature. <i>Clinical and Experimental Hepatology</i> , 2015, 1, 30-33.	1.3	14
75	Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis. <i>Medicine (United Tj ETQq1 10.784314rgBT /00</i>	1.0	14
76	Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C. <i>Journal of Dermatological Case Reports</i> , 2014, 8, 95-102.	1.1	5
77	O213: Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment-naive patients with HCV genotype 1: phase 3 COMMAND-3 results. <i>Journal of Viral Hepatitis</i> , 2014, 21, 7-8.	2.0	2
78	P1169 EFFECT OF PEGYLATED INTERFERON OR RIBAVIRIN DOSE REDUCTION DURING TELAPREVIR BASED THERAPY ON SVR12 IN NULL-RESPONDERS AND RELAPERS WITH ADVANCED LIVER FIBROSIS (ADVEX STUDY). <i>Journal of Hepatology</i> , 2014, 60, S474.	3.7	1
79	816 RIBAVIRIN DOSE REDUCTION DURING TELAPREVIR CONTAINING TRIPLE THERAPY DOES NOT AFFECT EARLY VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPERS WITH ADVANCED LIVER FIBROSIS. <i>Journal of Hepatology</i> , 2013, 58, S334-S335.	3.7	1
80	Distribution of HCV genotypes in Poland. <i>Przegląd Epidemiologiczny</i> , 2013, 67, 11-6, 99-103.	0.2	17
81	748 EFFICACY OF STANDARD OF CARE THERAPY FOLLOWING EXPERIMENTAL DEBIO 025 TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2010, 52, S291.	3.7	3
82	Extrahepatic manifestations associated with chronic hepatitis C infections in Poland. <i>Advances in Medical Sciences</i> , 2010, 55, 67-73.	2.1	16
83	Progress of liver disease in chronic hepatitis C patients who failed antiviral therapy. <i>Medical Science Monitor</i> , 2003, 9 Suppl 3, 25-8.	1.1	0
84	Assessment of selected clinical factors as predictors of response to combined interferon-alpha plus ribavirin therapy among patients with chronic hepatitis C. <i>Medical Science Monitor</i> , 2003, 9 Suppl 3, 32-5.	1.1	2